Novel treatment shows early promise in difficult to treat Hodgkin lymphoma and T-cell lymphomas

An early-phase trial of a new treatment called camidanlumab tesirine has produced promising response rates in people with lymphoma that has come back or not responded after several previous courses of treatment – people who typically have very limited treatment options.

Camidanlumab tesirine is an antibody-drug conjugate: an antibody joined to an anti-cancer drug. The antibody sticks to a protein called CD25, which is found on the surface of many lymphoma cells. It carries the drug straight to the lymphoma cells, wherever they are in the body.

The phase 1 trial included 133 people with Hodgkin or non-Hodgkin lymphoma. On average, the people who took part in the trial had had five previous courses of treatment, including 59 people who had had a stem cell transplant.

The trial found that camidanlumab tesirine produced high response rates in this difficult-to-treat group of people. The results were particularly encouraging in people with classical Hodgkin lymphoma or T-cell lymphomas. It is important to note that this is very early data and long-term follow-up isn’t available yet.

The treatment is now being studied further in ongoing trials.

To find out more about clinical trials for lymphoma, or to search for a trial that might be suitable for you, visit Lymphoma TrialsLink.

21 June 2021